Arrowhead Pharmaceuticals Quarterly Balance Sheet
NASDAQ: ARWRHealthcareBiotechnologyUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arrowhead Pharmaceuticals financial position
As of Jun 30, 2026, Arrowhead Pharmaceuticals reported total assets of $2.11 billion, up 53.0% from a year earlier against total liabilities of $1.65 billion. Shareholders' equity stood at $465.5 million, or 22.0% of assets. The company held $54.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 5.90, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Arrowhead Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q3 20262026-06-30 | Q2 20262026-03-31 | Q1 20262025-12-31 | Q4 20252025-09-30 | Q3 20252025-06-30 | Q2 20252025-03-31 | Q1 20252024-12-31 | Q4 20242024-09-30 | Q3 20242024-06-30 | Q2 20242024-03-31 | Q1 20242023-12-31 | Q4 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 54.76M | 188.52M | 201.64M | 226.55M | 129.79M | 185.71M | 53.89M | 102.69M | 69.40M | 127.70M | 58.20M | 110.89M |
| Short-Term Investments | 1.55B | 1.60B | 714.97M | 692.82M | 770.58M | 911.70M | 499.05M | 578.28M | 367.27M | 395.41M | 162.06M | 292.74M |
| Receivables | 8.56M | 15.69M | 218.87M | 6.82M | 9.70M | 2.37M | 2.50M | 0 | — | — | — | 0 |
| Total Current Assets | 1.67B | 1.84B | 1.17B | 950.64M | 946.92M | 1.14B | 570.54M | 695.47M | 450.06M | 541.65M | 237.90M | 416.47M |
| Property, Plant & Equipment | 373.30M | 374.82M | 378.58M | 382.51M | 381.05M | 384.80M | 387.07M | 386.03M | 375.91M | 359.25M | 333.41M | 290.26M |
| Intangible Assets | 5.59M | 6.01M | 6.44M | 6.86M | 7.29M | 7.71M | 8.14M | 8.56M | 8.99M | 9.41M | 9.84M | 10.26M |
| Total Assets | 2.11B | 2.27B | 1.60B | 1.39B | 1.38B | 1.57B | 1.01B | 1.14B | 883.76M | 955.15M | 626.29M | 765.55M |
| Accounts Payable | 27.78M | 30.75M | 32.94M | 17.67M | 33.05M | 9.98M | 14.46M | 11.39M | 26.55M | 8.52M | 4.46M | 35.87M |
| Total Current Liabilities | 283.35M | 295.22M | 347.43M | 195.49M | 194.53M | 220.54M | 93.76M | 103.17M | 96.71M | 65.17M | 63.72M | 105.46M |
| Total Liabilities | 1.65B | 1.67B | 1.04B | 881.88M | 860.81M | 889.27M | 957.62M | 948.74M | 544.78M | 459.75M | 452.57M | 478.39M |
| Shareholders' Equity | 465.53M | 613.98M | 568.42M | 466.05M | 522.31M | 683.32M | 52.59M | 185.44M | 330.55M | 483.79M | 160.41M | 271.34M |
| Retained Earnings | -1.92B | -1.73B | -1.60B | -1.63B | -1.60B | -1.43B | -1.80B | -1.63B | -1.45B | -1.28B | -1.16B | -1.03B |
| Net Cash (Debt) | 1.60B | 1.78B | 916.61M | 919.37M | 900.37M | 1.10B | 552.93M | 680.96M | 436.67M | 523.11M | 220.26M | 403.63M |
| Shares Outstanding | 141.13M | 140.57M | 137.39M | 135.70M | 138.14M | 138.06M | 125.57M | 124.38M | 124.23M | 124.13M | 107.50M | 107.31M |
This table shows 12 quarterly periods of Arrowhead Pharmaceuticals's balance sheet, from Q3 2026 back to Q4 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ARWR's reporting calendar. What is a balance sheet?